revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors, including the current status of our programs, on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2008, as well as in our other public filings, including our Management's Discussion and Analysis for the period ended May 31, 2009. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Summary financial tables are provided below.
(A DEVELOPMENT STAGE COMPANY)
Interim Consolidated Balance Sheets
Page: 1 2 3 4 5 6 7 8 9 10 Related biology technology :1
. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation2
. Vasogen Announces Third Quarter 2007 Results3
. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences4
. Vasogen Provides an Update on ACCLAIM-II Preparations5
. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure6
. Vasogen to Conduct Year-end 2007 Conference Call7
. Vasogen Announces 2007 Year-End Results8
. The Lancet Publishes Vasogens ACCLAIM Results9
. Vasogens Research Published in European Journal of Neuroscience10
. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel11
. Vasogen Provides Update on ACCLAIM II Program